Impact of targeted therapies on the risk of cardiovascular events in patients with psoriasis and psoriatic arthritis : A systematic review and aggregate data meta-analysis of randomized controlled trials
© 2023 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd..
OBJECTIVE: We aimed to investigate the effect of targeted therapies on cardiovascular risk in psoriasis (PsO) and psoriatic arthritis (PsA) via a meta-analysis of randomized controlled trials (RCTs).
METHODS: Pubmed, Embase, Cochrane Library, and Scopus were searched for RCTs reporting targeted therapies in patients with PsO/PsA published until 28 October 2021. The primary and secondary outcomes included the relationship between targeted therapies and all cardiovascular events (CVEs), major adverse cardiovascular events (MACEs), myocardial infarction (MI), heart failure, and stroke in PsO/PsA. The outcome risk ratios (RRs) were calculated using the Mantel-Haenszel fixed-effect method.
RESULTS: A total of 81 articles involving 88 RCTs were included. There was no statistically significant difference regarding the occurrence of all CVEs for all targeted therapies (RR = 1.03, 95% CI 0.74-1.43, P = .85) compared to placebo in PsO/PsA. No statistically significant difference existed between drugs and placebo in patients with PsA on all CVEs (RR = 0.81, 95% CI 0.48-1.36, P = .43). Surprisingly, the incidence of all CVEs was higher in the low dosage group compared to the high dosage group of all targeted therapies (RR = 1.97, 95% CI 1.19-3.27, P = .008) and prominently anti-interleukin-17 agent (RR = 2.20, 95% CI 1.05-4.58, P = .04).
CONCLUSION: Current targeted therapies are not associated with the risk of CVEs. Based on the existing evidence, we reported here that a dosage reduction of targeted therapies was not recommended.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:26 |
|---|---|
| Enthalten in: |
International journal of rheumatic diseases - 26(2023), 4 vom: 27. Apr., Seite 625-637 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cai, Ruyi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cardiovascular events |
|---|
| Anmerkungen: |
Date Completed 12.04.2023 Date Revised 12.04.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/1756-185X.14603 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM35269811X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM35269811X | ||
| 003 | DE-627 | ||
| 005 | 20231226054323.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/1756-185X.14603 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1175.xml |
| 035 | |a (DE-627)NLM35269811X | ||
| 035 | |a (NLM)36760030 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Cai, Ruyi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Impact of targeted therapies on the risk of cardiovascular events in patients with psoriasis and psoriatic arthritis |b A systematic review and aggregate data meta-analysis of randomized controlled trials |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.04.2023 | ||
| 500 | |a Date Revised 12.04.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd. | ||
| 520 | |a OBJECTIVE: We aimed to investigate the effect of targeted therapies on cardiovascular risk in psoriasis (PsO) and psoriatic arthritis (PsA) via a meta-analysis of randomized controlled trials (RCTs) | ||
| 520 | |a METHODS: Pubmed, Embase, Cochrane Library, and Scopus were searched for RCTs reporting targeted therapies in patients with PsO/PsA published until 28 October 2021. The primary and secondary outcomes included the relationship between targeted therapies and all cardiovascular events (CVEs), major adverse cardiovascular events (MACEs), myocardial infarction (MI), heart failure, and stroke in PsO/PsA. The outcome risk ratios (RRs) were calculated using the Mantel-Haenszel fixed-effect method | ||
| 520 | |a RESULTS: A total of 81 articles involving 88 RCTs were included. There was no statistically significant difference regarding the occurrence of all CVEs for all targeted therapies (RR = 1.03, 95% CI 0.74-1.43, P = .85) compared to placebo in PsO/PsA. No statistically significant difference existed between drugs and placebo in patients with PsA on all CVEs (RR = 0.81, 95% CI 0.48-1.36, P = .43). Surprisingly, the incidence of all CVEs was higher in the low dosage group compared to the high dosage group of all targeted therapies (RR = 1.97, 95% CI 1.19-3.27, P = .008) and prominently anti-interleukin-17 agent (RR = 2.20, 95% CI 1.05-4.58, P = .04) | ||
| 520 | |a CONCLUSION: Current targeted therapies are not associated with the risk of CVEs. Based on the existing evidence, we reported here that a dosage reduction of targeted therapies was not recommended | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Meta-Analysis | |
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a cardiovascular events | |
| 650 | 4 | |a psoriasis | |
| 650 | 4 | |a psoriatic arthritis | |
| 650 | 4 | |a targeted disease-modifying antirheumatic drugs | |
| 700 | 1 | |a Jin, Yinji |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Beidi |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Jinxia |e verfasserin |4 aut | |
| 700 | 1 | |a Zhai, Jiayu |e verfasserin |4 aut | |
| 700 | 1 | |a Zeng, Lin |e verfasserin |4 aut | |
| 700 | 1 | |a Mu, Rong |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of rheumatic diseases |d 2009 |g 26(2023), 4 vom: 27. Apr., Seite 625-637 |w (DE-627)NLM197180566 |x 1756-185X |7 nnns |
| 773 | 1 | 8 | |g volume:26 |g year:2023 |g number:4 |g day:27 |g month:04 |g pages:625-637 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/1756-185X.14603 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 26 |j 2023 |e 4 |b 27 |c 04 |h 625-637 | ||